According to Insight Life's announcement, the four medical device registration applications for anti-epileptic drug concentration measurement kits declared by the holding subsidiary Shanghai Maishi Biotechnology Co., Ltd. were recently accepted by the Shanghai Drug Administration. Currently, the registration application is in the acceptance stage, and technical review, administrative approval, and approval procedures are still required.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.